Patent intelligence · US
US 9636515
Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use
Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for thera…
Patent details — US 9636515
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 2, 2017
- Expiration
- Apr 27, 2037
- Claims
- 15
- CPC classes
- A61K, A61K35/12, A61K35/16, A61K35/28
Quick answer
US 9636515 (Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use) is held by Advanced Neuroregenerative Therapies, LLC.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K35/12, A61K35/16, A61K35/28, A61K38/18, A61K38/193
More from Advanced Neuroregenerative Therapies, LLC.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9636515?
US 9636515 (Method of repairing age and disease immune dysfunction and cellular senescence with lymphoid stem cells and then re-applying those for therapeutic use) is held by Advanced Neuroregenerative Therapies, LLC.. Status: granted. Granted May 2, 2017. Expires Apr 27, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9636515?
Advanced Neuroregenerative Therapies, LLC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9636515 expire?
Our index shows an expiration date of Apr 27, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.